Fatal Salmonella enteritidis septicaemia in a rheumatoid arthritis patient treated with a TNF-alpha antagonist.
We report a patient with a rare presentation of extra-intestinal salmonellosis after infliximab therapy for rheumatoid arthritis. We discuss the increasing incidence of primary infections and reactivation of intracellular microorganisms after treatment with TNF-alpha blockage, with emphasis on salmonellosis.
Rijkeboer
Annemieke
A
Department of Internal Medicine, VU University Medical Centre, Amsterdam, The Netherlands.
Voskuyl
Alexandre
A
Van Agtmael
Michiel
M
D000368:Aged; D000785:Aneurysm, Infected / Q000382:microbiology*; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy; D016724:Empyema, Pleural / Q000150:complications / Q000276:immunology / Q000382:microbiology*; D017809:Fatal Outcome; D006801:Humans; D000069285:Infliximab; D008297:Male; D012480:Salmonella Infections / Q000150:complications* / Q000276:immunology; D012477:Salmonella enteritidis / Q000472:pathogenicity*; D018805:Sepsis / Q000382:microbiology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab